BXP (BXP) Secures $1.2b Madison Loan, Is It Still 22% Below Fair Value?
BXP (BXP) shares are in focus after the company closed a $1.2b construction loan tied to its 343 Madison Avenue project in Midtown Manhattan, a key financing step for the $2b development.
See our latest analysis for BXP.
The construction loan news lands after a mixed share price run for BXP, with a 90 day share price return of 15.78% but a 5 year total shareholder return that is still down 24.13%. Recent events include the updated 2026 earnings guidance, second quarter results, and the revised full year earnings outlook.
If this kind of large project financing has your attention, it can be worth broadening your search using Simply Wall St's screener for other real asset heavy businesses. A good place to start is the 20 top founder-led companies
BXP now trades about 22% below an estimated intrinsic value and close to 8% under the average analyst target, even after its recent rebound. Does that discount still reflect justified caution on earnings and development risk?
Most Popular Narrative: 30% Undervalued
The most followed narrative pegs BXP's fair value at $69.05, very close to the last close of $68.81, yet still flags a discount that investors are watching closely.
BXP's aggressive capital recycling and asset sales strategy (targeting $600 million in non-core dispositions), along with redevelopment and adaptive reuse of assets for mixed-use and multifamily, is expected to unlock higher-yielding income streams, fortify net margins, and provide non-dilutive funding for growth, supporting future FFO and earnings resilience.
Want to see what sits behind that confidence in BXP's cash flow story? The narrative leans on measured revenue growth, stable margins, and a punchy future earnings multiple that assumes investors are willing to pay up for those projected numbers.
Result: Fair Value of $69.05 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, BXP's story still hinges on improving office demand and life science leasing, while the $2b 343 Madison project adds meaningful capital and refinancing risk.
Find out about the key risks to this BXP narrative.
Next Steps
With BXP's mix of risks around development and demand, and the potential rewards investors are hoping to see, it makes sense to review both sides carefully and move quickly to your own view using these 3 key rewards and 4 important warning signs
Looking for more investment ideas beyond BXP?
If BXP has sharpened your focus on quality and risk, do not stop here. Use these targeted stock ideas to pressure test and strengthen your broader portfolio.
- Target resilient cash generators with dependable income streams by scanning companies built around strong payouts using the 8 dividend fortresses
- Zero in on quality at a discount and compare BXP with peers that score well on both fundamentals and pricing through the 49 high quality undervalued stocks
- Prioritize peace of mind by focusing on companies that show sturdier balance sheets and lower overall risk using the 78 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com